Member of the Expert Committee for the Generic & Biosimilar Medicines Programme
Alex Bernhardt is a member of the 2022 Expert Review Committee for the Generic & Biosimilar Medicines Programme. Alex is responsible for BNP Paribas Asset Management’s Sustainability research agenda and ESG scoring platform, and manages a global team of ESG analysts. An acknowledged sustainable finance thought leader and innovator, Alex has received multiple awards for his work within insurance and investment across topics including climate risk management, ESG integration and impact investing.
Alex joined from Marsh McLennan, where he was Director of Innovations, helping clients to address systemic issues including climate resilience, the catastrophe protection gap, diversity and sustainable infrastructure financing.
He was previously Principal and US Responsible Investment Leader at Mercer, helping institutional investors to manage sustainability challenges in their portfolios, particularly related to climate change. He joined Mercer from reinsurance broker Guy Carpenter where, among other things, he devised bespoke microinsurance programs for low-income communities worldwide.
Alex holds a BA in English from the University of Puget Sound in Tacoma, Washington.